Komipharm International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 01:56 am EST
Share
Komipharm International Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 243.88 million compared to KRW 377.34 million a year ago. Net loss was KRW 1,413.79 million compared to KRW 981.8 million a year ago. Basic loss per share from continuing operations was KRW 20 compared to KRW 13.6364 a year ago. Diluted loss per share from continuing operations was KRW 20 compared to KRW 13.6364 a year ago. Basic loss per share was KRW 22 compared to KRW 15 a year ago.
For the nine months, sales was KRW 864.26 million compared to KRW 1,367.28 million a year ago. Net loss was KRW 2,966.79 million compared to net income of KRW 26.66 million a year ago. Basic loss per share from continuing operations was KRW 41.8182. Diluted loss per share from continuing operations was KRW 41.8182. Basic loss per share was KRW 45.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
KOMIPHARM INTERNATIONAL CO., LTD. 
